Novartis, GSK, Lilly sign multibillion-dollar deals to trade business units
GENEVA - Drugmaker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Lilly that will affect some 15,000 of its employees.
The Basel, Switzerland-based company said Tuesday it will buy GSK's oncology products business for $14.5 billion, plus up to $1.5 billion more if certain milestones are met.
It will also divest its vaccines business to GSK, excluding its flu business, for $7.1 billion, plus royalties. The two companies are also creating a new consumer health care business through a joint venture.
Separately, Novartis said it will sell off its animal health division to Lilly for about $5.4 billion and plans to sell its flu business.
Novartis CEO Joseph Jimenez told reporters the transactions will raise profits and "affect 15,000 Novartis employees," but didn't specify in which way.
Read more Business News
- Smith Creek: low erosion riskWest Kelowna - 10:29 am
- Alerts rescinded in RDOSPenticton / S. Okanagan - 10:00 am
- Wind knocks tree onto homeKelowna
- Hwy. 1 & 97A reopenBC - 1:17 am
|QHR Technologies Inc||1.16||+0.01|
|Anavex Life Sciences||0.29||-0.035|
|Copper Mountain Mining||2.79||+0.03|
|Sunrise Resources Ltd||0.025||-0.005|
|Mission Ready Services||0.19||+0.01|
The Big Picture Geopolitical tensions rattle markets The spectre of rising geopolitical tensions in Ukraine and Gaza cast a shadow over an otherwise positive week in the markets. News that a passenger...
The mainstream media are finally waking up to something unusual in British Columbia – a labour shortage. If the experience of Alberta is a guide to our own future, the highly skilled labour will...
Photo: ContributedI have the pleasure of witnessing people delegate tasks quite often. Sometimes with tremendous success and sometimes with disastrous consequences. I have chaired a lot of committees...